Skip to main content

Can you take Docusate with Enzalutamide?

1 drug interaction and 8 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

docusate enzalutamide

Applies to: docusate and enzalutamide

Enzalutamide can cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.

The risk is increased if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances, such as low blood levels of magnesium or potassium

These electrolyte disturbances can occur with bowel cleansing preparations or excessive use of medications that have a laxative effect, such as docusate.

Do not exceed the dose and duration recommended on the product label or prescribed by your doctor.

You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether taken together or separately.

In addition, you should let your doctor know if you experience signs and symptoms of low magnesium or potassium blood level such as:

  • weakness
  • tiredness
  • drowsiness
  • dizziness
  • confusion
  • tingling
  • numbness
  • muscle pain
  • cramps
  • nausea
  • vomiting

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

8 potential interactions Applies to: 8 conditions, including Seizures, Head Injury, Inflammatory Bowel Disease, Brain Tumor, and Renal Dysfunction.

Brain Tumor

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with Brain Tumor.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

CNS Infection

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with CNS Infection.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Gastrointestinal Obstruction

Major:

docusate

Docusate has a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

Head Injury

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with Head Injury.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

History - Cerebrovascular Disease

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Inflammatory Bowel Disease

Major:

docusate

Docusate has a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Renal Dysfunction

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with Renal Dysfunction.

Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.

Seizures

Moderate:

enzalutamide

Enzalutamide has a moderate potential interaction with Seizures.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Report options

Loading...
QR code containing a link to this page

More resources

docusate

A total of 203 drugs are known to interact with docusate.

enzalutamide

A total of 703 drugs are known to interact with enzalutamide.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer